Medtronic Releases Positive Results Of LATERAL Clinical Trial
Zacks Investment Research | Jul 10, 2019 08:22AM ET
Medtronic plc (NYSE:MDT) recently announced favorable two-year outcomes from the LATERAL clinical trial. It evaluated the use of the company’s HeartWare HVAD System in patients, who received treatment on the system via a less-invasive, thoracotomy implant approach. These results proved to be significant progress for the global major in the field of cardiovascular treatment.
Outcome of the Study in Detail
The HVAD Pump is the world’s smallest, commercially available, full-support, centrifugal Left Ventricular Assist Device (LVAD). Further, it is the only full-support LVAD with clinical evidence highlighting its safety and efficacy when implanted via a less-invasive thoracotomy approach. It helps to increase blood circulation in patients, who are suffering from advanced heart failure.
After two years of follow up, the data highlighted that 95% of patients, who implanted HVAD via thoracotomy, did not face further possibility of incapacitating stroke.
Additionally, there were a few other positive outcomes of this study. For instance, a review of adverse events occurring in the LATERAL trial proved that such events were more likely to occur during the first 30 days after the implant, with a significant decline in bleeding, arrhythmia and stroke. The overall rate of adverse events significantly lessened one to six months after the implant. Further, the risk of stroke after the implant was minimal.
Market Prospects
Per Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.